论文精选

ImmuneAgent 系统从人 B 细胞库中发现广谱中和抗体

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

精选理由

一个把 AI 推理和湿实验闭环起来的抗体发现系统,110 个候选里 60 个真中和,还顺带找到了 bnAb 的细胞来源,免疫学背景的读者别错过。

ImmuneAgent 是一个闭环 AI 系统,结合多模态推理、持续元学习与湿实验反馈,用于从无标记的人 BCR 库中筛选广谱中和抗体。

正文

在 110 个克隆候选中实现约 55% 的中和抗体发现率(60/110)和约 11% 的 bnAb 产率(12/110),超过同克隆预算下的序列中和预测器与 cofolding 模型。其中 5 个抗体在小鼠流感致死攻击模型中提供 100% 保护,效果与临床阶段疗法 MEDI8852 相当。

系统还发现 FCRL5+CD27+ 非典型记忆 B 细胞是 bnAb 的保守来源,并将方法泛化到 hMPV 与 HPV,无需抗原特异性分选即可发现中和抗体。

原文 · arXiv cs.AI

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

产业坐标与信源核验

本条情报归属 AITOP「论文」核心栏目,重点聚焦北美前沿实验室与硅谷科技巨头。在跨区域产业观察坐标中,该动态直接关联「AI 开发者工具链、Coding Agent 与工程化实践」研究主线,反映出当前技术演进与商业落地的最新风向。涉及核心实体与技术议题包括:ImmuneAgent、广谱中和抗体、多模态、AI制药,读者可通过下方标签进入对应专题页查阅历史脉络与关联对比。

信源核验说明:本文原始线索采编自「arXiv cs.AI」(@Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao, Yu Chen, Mengting Huang, Yupeng Yang, Qianyu Pan, Nana Fu, Yansong Shi, Hongli Li, Yangyang Chai, Ruyi Chen, Wansheng Li, Zhu Liang, Rongmei Yao, Yuanhan Mo, Lei Wang, Chunmei Wang, Yun Quan, Qiong Zhang, Xiangxi Wang, Xuetao Cao),经 AITOP 多维评分管线结构化提炼。